Santiago Fontes, Medical Oncologist, Immuno-Oncology Specialist, shared a post on LinkedIn:
“ASCO Plenary Session; RAS is no longer UN-DRUGGABLE
For decades, RAS was considered the archetypal “undruggable” target, representing one of the greatest challenges in oncology.
Today, that paradigm has shifted.
The presentation of the RASolute trial at the ASCO Annual Meeting 2026 highlights the remarkable progress being made in targeting RAS-driven cancers and further reinforces the transition from therapeutic nihilism to precision medicine; specially in pancreatic cancer!!
While resistance mechanisms and patient selection remain critical challenges, the momentum in RAS-directed therapies is undeniable.
RAS is no longer undruggable—it is increasingly actionable.”
Other articles featuring Santiago Fontes.